Q4 2024 · 13F-HR
SR ONE CAPITAL MANAGEMENT, LPholdings as filed
Filed 2025-02-13 · accession 0000950123-25-002049
$410.1M
Reported value
11
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03940C100 | ACLXGBX | Arcellx, Inc. | $180.0M | 43.9% | 2,346,630 | Common | SOLE |
| 82835W108 | SPRY | ARS Pharmaceuticals, Inc. | $42.3M | 10.3% | 4,012,903 | Common | SOLE |
| H17182108 | CRSP | CRISPR Therapeutics AG | $41.3M | 10.1% | 1,048,951 | Common | SOLE |
| 25056L103 | DSGN | Design Therapeutics, Inc. | $40.3M | 9.82% | 6,526,476 | Common | SOLE |
| 98937L105 | ZBIO | Zenas BioPharma, Inc | $40.2M | 9.81% | 4,911,539 | Common | SOLE |
| 603170101 | MLYS | Mineralys Therapeutics Inc. | $24.8M | 6.05% | 2,016,822 | Common | SOLE |
| 022307102 | ALMS | Alumis Inc. | $15.4M | 3.76% | 1,959,896 | Common | SOLE |
| 687604108 | ORKA | Oruka Therapeutics, Inc | $8.3M | 2.03% | 430,330 | Common | SOLE |
| 65487U108 | NKTX | Nkarta, Inc. | $8.3M | 2.02% | 3,333,333 | Common | SOLE |
| 29286M105 | — | enGene Holdings Inc. | $5.0M | 1.21% | 747,750 | Common | SOLE |
| 483119202 | KALAEUR | KALA Bio, Inc. | $4.2M | 1.01% | 598,940 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.